Boston Scientific Craters 17% — When "Beating the Odds" Isn't Enough
Boston Scientific's stock plummeted 17% after missing future outlook projections, despite beating earnings expectations. This episode of Implied discusses the factors contributing to the stock's decline, including competition and concerns about its core products.